Oppenheimer Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Justin Kim has maintained an Outperform rating on Apellis Pharmaceuticals (NASDAQ:APLS) but has reduced the price target from $88 to $75.

December 15, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Apellis Pharmaceuticals' Outperform rating is maintained by Oppenheimer, but the price target is lowered from $88 to $75.
While the Outperform rating suggests that Oppenheimer still sees Apellis Pharmaceuticals as a good investment, the reduction in the price target could imply a tempered expectation for the stock's growth potential in the short term. This might lead to mixed reactions in the market, with some investors seeing the lowered target as a sign of caution, while others may focus on the continued positive outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100